A
It is fascinating to see the shift from "chronic management" toward "durable resolution" in the context of Diabetic Macular Edema (DME). The editorial by Ophir A. highlights a crucial evolution in how we categorize the disease—moving away from a "one-size-fits-all" anti-VEGF approach toward identifying the specific anatomical driver of the edema.
Based on the snippet you provided, here is a breakdown of these "potentially curative" pathways:
1. Two Distinct Pathogenetic Mechanisms
The core of this approach is recognizing that DME isn't a monolithic condition. By identifying the specific source of fluid, clinicians can move from repetitive injections to targeted interventions:
Microaneurysm (MA)-related DME: This is driven by focal leaks from tiny bulges in the retinal blood vessels. While drugs like Faricimab address the systemic signaling (VEGF and Ang-2), direct focal laser or specific targeting of these MAs can sometimes lead to a "dry" macula with fewer interventions.
Vitreo-tractional DME: This occurs when the vitreous gel pulls on the retina, causing mechanical leakage. In these cases, no amount of medication will "cure" the edema because the cause is physical. A surgical intervention (vitrectomy) to release that tension can be a definitive solution.
2. The Role of Faricimab (Vabysmo)
The "Revisiting Faricimab" aspect likely refers to its dual-pathway inhibition. Unlike older generation drugs that only block VEGF, Faricimab also blocks Ang-2.
Ang-2 is associated with vascular instability and inflammation.
By blocking both, Faricimab aims to "dry" the retina faster and keep it dry longer, which is a major step toward reducing the treatment burden that plagues DME patients.
3. Toward "Durable Macular Dryness"
The editorial suggests that if there is no overt ischemia (lack of blood flow), treating the specific cause—rather than just the symptoms—could lead to long-term stability. This is a bold departure from the traditional view of DME as a life-long, repetitive injection cycle.
In Practice
If you are looking at this from a clinical or research perspective, the "practice" here is Differential Diagnosis. Before starting a standard injection protocol, the clinician asks:
Is this fluid coming from a leaky MA? 2. Is there a vitreous membrane pulling on the macula? Would you like me to look for more specific data on the Faricimab trial results (YOSEMITE and RHINE) mentioned in the editorial, or perhaps a deeper dive into the surgical outcomes for vitreo-tractional DME?
No comments:
Post a Comment